Last reviewed · How we verify

NCT06594549: NUS1000SE

Sleep Health, Workplace Stress and Wellbeing in NUS Staff: the NUS1000 Staff Edition Study

Not yet recruiting Last updated 19 September 2024
What this trial tests

trial in Life Experiences in 1,000 participants. Not yet recruiting.

Timeline
1 November 2024
Primary endpoint
1 November 2025
1 November 2025

Quick facts

Lead sponsorNational University of Singapore
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 November 2024
Primary completion1 November 2025
Estimated completion1 November 2025
Sites1 location across Singapore

Conditions studied

Sponsor

National University of Singapore

Who can join

Adults 35 to 70, any sex, with Life Experiences. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Workplace stress can significantly affect workers sleep, physical health and mental wellbeing. Recognizing and characterizing obstacles to healthy sleep patterns in office workers can help identify targets for corporate interventions that improve productivity and workplace wellbeing. Following the investigator\'s experience with the NUS1000 study in 1st year students conducted in Aug-Dec 2023, the investigators will now track daily sleep, wellbeing and time-use in NUS staff for 1 year in the present study. These data will reveal work-related stressors that impact daily sleep and mood. In addition, the investigators will investigate whether daily sleep and stress are associated with cardiovascular health in this middle-age cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National University of Singapore trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06594549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing